...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: RVX-297 vs RVX-208 for autoimmune indications

Well, if selectivity is what you are looking for then you may be interested in Abbvie's ABBV-744 with its reported 300-fold BD-2 selectivity. It's in Phase 1 for oncology. 

BearDownAZ

Share
New Message
Please login to post a reply